Saama Technologies, Inc., the number one AI clinical analytics platform company, announced that it signed an agreement with Pfizer Inc. to develop and deploy an AI-powered analytics solution to reduce the challenges commonly experienced by clinical study data managers and monitors. Under this agreement, Saama’s award-winning Life Science Analytics Cloud (LSAC) platform will aggregate, transform, analyze, model and predict clinical data queries using deep learning techniques. Pfizer will provide the required ground truth clinical data and domain expertise to train Saama models to achieve the required accuracy.
“Historically, our industry has been limited to manual, inefficient data review processes to validate data from our clinical trials”
“Saama is pioneering transformational changes to the way clinical study data is managed and understood by pharma, since current processes and systems are mostly manual and take a significant amount of time,” said Sagar Anisingaraju, Chief Strategy Officer, Saama Technologies. “As part of this collaboration with Pfizer, the deep learning models of LSAC will be further trained and improved to provide augmented intelligence, empowering data managers to operate more efficiently and effectively. Saama appreciates the leadership role that Pfizer is taking to solve this industry-wide problem by providing valuable clinical data across therapeutic areas for training our smart data query solution.”
Recommended AI News: Rockset Gains Momentum as the Industry’s Leading Real-Time Database in the Cloud
“Historically, our industry has been limited to manual, inefficient data review processes to validate data from our clinical trials,” said Demetris Zambas, Pfizer Vice President and Head of Data Monitoring and Management. “Through our strategic collaboration with Saama Technologies, we’ve identified efficiencies to improve processes and experiences for our clinical research partners.”
Recommended AI News: Hyperledger Fabric 2.0 Arrives to Boost Enterprise Blockchain Adoption
Comments are closed, but trackbacks and pingbacks are open.